|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.47 - 86.46|
|52 Week Range||67.42 - 89.09|
|PE Ratio (TTM)||41.15|
|Earnings Date||Jan 31, 2018|
|Forward Dividend & Yield||2.08 (2.44%)|
|1y Target Est||91.55|
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates. The company said it would not seek a regulatory approval based on the results. The study tested Cyramza in combination with other drugs as a first-line treatment for patients with advanced forms of gastric cancer, which is estimated to result in the deaths of nearly 11,000 people in the United States this year.
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a treatment for a type of gastric cancer met its main goal of preventing the disease from advancing. However the trial failed ...
INDIANAPOLIS , Dec. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA ® (ramucirumab) in combination with cisplatin and ...
In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.
In 3Q17, Eli Lilly’s (LLY) Adcirca generated revenues of $25.4 million, a ~14% increase on a year-over-year (or YoY) basis and 11% growth on a quarter-over-quarter basis.
Examining how Eli Lilly and Company (NYSE:LLY) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...
TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.
INDIANAPOLIS, Dec. 5, 2017 /PRNewswire/ -- Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by Eli Lilly and Company (LLY). The AID system is part of the Connected Diabetes Ecosystem, which is being designed to make diabetes management easier by enabling people to use insulin more effectively.
Stock Monitor: AstraZeneca Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 05, 2017 / Active-Investors issued a free report on Eli Lilly and Co. (NYSE: LLY ), which is readily accessible upon ...
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
As of November 22, 2017, of the 22 analysts tracking Eli Lilly stock, 13 recommend a “buy,” while eight recommend a “hold,” and one recommends a “sell.”
- Psoriatic arthritis is the second approved indication for Taltz in the United States(1) - INDIANAPOLIS , Dec. 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food ...
In 3Q17, Eli Lilly surpassed the analysts’ estimates for EPS (earnings per share) and revenues, reporting EPS of $1.05 on revenues of ~$5.7 billion.
Eli Lilly's 3Q17 performance was positive in both major segments due to the inclusion of the Boehringer Ingelheim Vetmedica portfolio.
Today we’re going to rank the longest-lasting dividends on the planet – five stocks that have written checks to shareholders for at least a century . Dividends don’t get more secure than that. Think about what the world was like in 1917. The United ...
TheStreet Inc. founder Jim Cramer predicts the ink on these 12 deals drying in 2018. Here's what you need to know, from Qualcomm to Disney to General Electric.
Eli Lilly's Animal Health segment, also known as Elanco, reported revenues of $740.6 million during 3Q17, representing a 5% YoY rise.